Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

628 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). Kaifie A, et al. Among authors: berdel we. Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. Epub 2016 Jun 22. Ann Hematol. 2016. PMID: 27334946
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). Kaifie A, et al. Among authors: berdel we. J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9. J Hematol Oncol. 2016. PMID: 26944254 Free PMC article.
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
Brunnberg U, Mohr M, Noppeney R, Dürk HA, Sauerland MC, Müller-Tidow C, Krug U, Koschmieder S, Kessler T, Mesters RM, Schulz C, Kosch M, Büchner T, Ehninger G, Dührsen U, Serve H, Berdel WE. Brunnberg U, et al. Among authors: berdel we. Ann Oncol. 2012 Apr;23(4):990-6. doi: 10.1093/annonc/mdr346. Epub 2011 Aug 2. Ann Oncol. 2012. PMID: 21810729 Free article. Clinical Trial.
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.
Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler US; Study Alliance Leukemia (SAL). Röllig C, et al. Among authors: berdel we. Ann Oncol. 2018 Apr 1;29(4):973-978. doi: 10.1093/annonc/mdy030. Ann Oncol. 2018. PMID: 29390048 Free article. Clinical Trial.
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saußele S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK). Proetel U, et al. Ann Hematol. 2014 Jul;93(7):1167-76. doi: 10.1007/s00277-014-2041-0. Ann Hematol. 2014. PMID: 24658964 Free PMC article. Clinical Trial.
Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.
Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL). Heidrich K, et al. Among authors: berdel we. Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500. Ann Oncol. 2017. PMID: 28945881 Free article.
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group. Müller-Tidow C, et al. Among authors: berdel we. Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2. Leukemia. 2016. PMID: 26522083 Clinical Trial.
Karyotype complexity and prognosis in acute myeloid leukemia.
Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G. Stölzel F, et al. Among authors: berdel we. Blood Cancer J. 2016 Jan 15;6(1):e386. doi: 10.1038/bcj.2015.114. Blood Cancer J. 2016. PMID: 26771812 Free PMC article.
628 results